#United States #Sanford #CAREstream America #Celltermi #CHA Bio Group

A New Era in Aesthetic Solutions

CAREstream America, a prominent player in the distribution of medical solutions for hospitals and aesthetics, has recently announced a significant development that could reshape the US aesthetic market. Through an exclusive partnership with CHA Meditech, they are set to introduce Celltermi HS and NX Plus—two groundbreaking products powered by probiotic-derived microbiome technology.

This marks a pivotal moment for both companies, who are united by a common vision to advance the science behind skin and hair care. The Celltermi offerings are the result of meticulous research and development, drawing on CHA Bio Group's 65 years of expertise in the field of biomaterials.

A Commitment to Quality and Trust

Blake Petrunick, CEO of CAREstream America, emphasized the importance of trust in a rapidly evolving market. "In a rapidly evolving market, practitioners are seeking partners and products they can trust. Our decision to partner with CHA Bio Group was driven by the strength of its foundation, patented technology, and commitment to rigorous standards," he stated. This dedication to quality ensures that health professionals can confidently adopt these innovative solutions into their practices.

Unlike many products that may oversell their efficacy, the Celltermi sets are crafted with a strong emphasis on manufacturing integrity and scientific validation. This attention to detail ensures that practitioners are equipped with reliable products designed for today's demanding aesthetic treatments.

The Science Behind Celltermi

The Celltermi tech leverages proprietary components that have been developed with the support of a renowned South Korean biomaterials organization known for its pioneering advancements in regenerative technology. The products integrate advanced cell research and innovations in exosome and biomaterial technologies, which are expected to elevate the standards of the aesthetic market in the United States.

Sokjin Kim, CEO of CHA Meditech, highlighted how their collaboration with CAREstream will facilitate the introduction of these next-generation solutions. He stated, "Our exclusive partnership with CAREstream America marks a significant milestone in bringing next-generation aesthetic solutions to the US market. With our combined resources, we aspire to establish a new benchmark for quality and efficacy in the aesthetics industry."

Availability and Future Prospects

The Celltermi HS and NX Plus products are now available for qualified providers and practices across the United States, marking the beginning of a new chapter in aesthetic solutions. In a market that continually seeks innovative and effective treatments, this partnership reflects a shared vision of prioritizing transparency, innovation, and scientifically grounded product development.

Both CAREstream America and CHA Meditech recognize that elevating the standards in aesthetic solutions is key to satisfying the evolving needs of practitioners and patients alike. As they embark on this journey together, the focus remains on delivering trusted, cutting-edge solutions that align with modern-day aesthetic practices.

About CHA Bio Group and CAREstream America

CHA Meditech is a subsidiary of the globally recognized CHA Bio Group and specializes in high-quality medical devices and aesthetic solutions. Their portfolio includes internationally renowned hyaluronic acid fillers and has a strong presence in over 30 countries.

On the other hand, CAREstream America is dedicated to enhancing the lives of healthcare professionals and patients through comprehensive healthcare solutions. Their growing portfolio spans several specialties, including aesthetics, showcasing their commitment to quality and efficiency in medical practice.

For more information about these innovative products and the mission of both companies, visit the CAREstream America website.